NASDAQ:FATE - Fate Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.04 -0.53 (-3.20 %) (As of 01/18/2019 04:00 PM ET)Previous Close$16.04Today's Range$15.57 - $16.8552-Week Range$6.76 - $17.98Volume749,313 shsAverage Volume814,129 shsMarket Capitalization$1.07 billionP/E Ratio-15.73Dividend YieldN/ABeta2.03 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells; and a collaboration agreement with ONO Pharmaceutical Co., Ltd. for the development and commercialization of two off-the-shelf CAR-T cell product candidates. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California. Receive FATE News and Ratings via Email Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FATE Previous Symbol CUSIPN/A Webwww.fatetherapeutics.com Phone858-875-1800Debt Debt-to-Equity Ratio0.07 Current Ratio9.44 Quick Ratio9.44Price-To-Earnings Trailing P/E Ratio-15.73 Forward P/E Ratio-13.26 P/E GrowthN/A Sales & Book Value Annual Sales$4.11 million Price / Sales252.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.51 per share Price / Book10.62Profitability EPS (Most Recent Fiscal Year)($1.02) Net Income$-42,950,000.00 Net Margins-1,536.05% Return on Equity-68.57% Return on Assets-50.27%Miscellaneous Employees80 Outstanding Shares64,600,000Market Cap$1.07 billion OptionableOptionable Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions What is Fate Therapeutics' stock symbol? Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE." How were Fate Therapeutics' earnings last quarter? Fate Therapeutics Inc (NASDAQ:FATE) released its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.06. The biopharmaceutical company earned $1.03 million during the quarter, compared to analysts' expectations of $1.24 million. Fate Therapeutics had a negative return on equity of 68.57% and a negative net margin of 1,536.05%. The business's quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the business earned ($0.26) earnings per share. View Fate Therapeutics' Earnings History. When is Fate Therapeutics' next earnings date? Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 4th 2019. View Earnings Estimates for Fate Therapeutics. What price target have analysts set for FATE? 8 analysts have issued 12 month price targets for Fate Therapeutics' shares. Their forecasts range from $12.00 to $23.00. On average, they anticipate Fate Therapeutics' stock price to reach $18.5714 in the next year. This suggests a possible upside of 15.8% from the stock's current price. View Analyst Price Targets for Fate Therapeutics. What is the consensus analysts' recommendation for Fate Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics. What are Wall Street analysts saying about Fate Therapeutics stock? Here are some recent quotes from research analysts about Fate Therapeutics stock: 1. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (1/7/2019) 2. HC Wainwright analysts commented, "Our $12 price target is based on a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for ProTmune and FATE-NK100. We use the net present value of our revenue forecast through 2026, apply a 40% probability of success for 2Q18 fully diluted net cash estimate of $0.84/share to arrive at our $12 price target. We value the early stage pipeline and Juno collaboration at $2.32/share. We assume a 25% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (8/7/2018) Has Fate Therapeutics been receiving favorable news coverage? Media headlines about FATE stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fate Therapeutics earned a news impact score of 0.9 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days. Who are some of Fate Therapeutics' key competitors? Some companies that are related to Fate Therapeutics include Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Spark Therapeutics (ONCE), Regenxbio (RGNX), Editas Medicine (EDIT) and Autolus Therapeutics (AUTL). Who are Fate Therapeutics' key executives? Fate Therapeutics' management team includes the folowing people: Mr. J. Scott Wolchko, Founder, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 49)Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 51)Dr. Chris M. Storgard, Consultant (Age 53)Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 46)Mr. Jim Beitel M.B.A., Sr. VP of Corp. Devel. Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Boston Advisors LLC (0.10%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Cindy Tahl, Daniel D Shoemaker and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics. Which institutional investors are buying Fate Therapeutics stock? FATE stock was purchased by a variety of institutional investors in the last quarter, including Boston Advisors LLC. View Insider Buying and Selling for Fate Therapeutics. How do I buy shares of Fate Therapeutics? Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fate Therapeutics' stock price today? One share of FATE stock can currently be purchased for approximately $16.04. How big of a company is Fate Therapeutics? Fate Therapeutics has a market capitalization of $1.07 billion and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-42,950,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Fate Therapeutics employs 80 workers across the globe. What is Fate Therapeutics' official website? The official website for Fate Therapeutics is http://www.fatetherapeutics.com. How can I contact Fate Therapeutics? Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected] MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 291 (Vote Outperform)Underperform Votes: 170 (Vote Underperform)Total Votes: 461MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: What is Liquidity?